

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2315)

NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2026 second extraordinary general meeting (the “EGM”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”) will be held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online at 2:00 p.m. on Thursday, June 25, 2026 for the following purposes of considering and, if deemed appropriate, approving the following resolutions.

ORDINARY RESOLUTION

1. To consider and approve the proposed formulation of Remuneration Management System for Directors and Senior Management.

SPECIAL RESOLUTIONS

2. To consider and if thought fit, pass with or without amendments, the following resolution regarding the proposed granting of general mandate to repurchase H Shares:

“THAT:

- (a) Subject to the restrictions set forth in paragraph (b) and (c) below, the exercise by the Board during the Relevant Period (as defined below) of all the powers of the Company to repurchase the H Shares listed on the Stock Exchange, subject to and in accordance with all applicable laws, regulations and rules and/or requirements of the governmental or regulatory body of securities in the PRC, the Stock Exchange or any other governmental or regulatory body be and is hereby approved;
- (b) The total number of H Shares authorized to be repurchased by the Company pursuant to the approval mentioned above during the Relevant Period (as defined below) shall not exceed 10% of the Company’s total number of H Shares (excluding any treasury shares) in issue as at the date of the EGM, which represent approximately 2.48% of the Company’s total issued share capital as at the date of the EGM;

- (c) The approval in (a) above shall be conditional upon satisfaction of all the following conditions:
 - (i) The obtainment of approval at the EGM;
 - (ii) The obtainment of approval from all relevant regulatory authorities having jurisdiction over the Company (if applicable) as required by the laws, regulations and rules of the PRC; and
 - (iii) The Company not being required by any of its creditors to repay or to provide guarantees in respect of any amount due to any of them (or if the Company is so required by any of its creditors, the Company having, at its absolute discretion, repaid or provided guarantee in respect of such amount) pursuant to the notification procedures under the PRC Company Law and the Articles of Association. If the Company determines to repay any amount to any of its creditors, the Company will do so out of its internal funds.

- (d) Subject to the approval of all relevant government authorities in the PRC for the repurchase of such shares of the Company being granted and subject to the abovementioned conditions, the Board be and is hereby authorized to:
 - (i) Formulate and implement the specific repurchase plans, including but not limited to repurchase price and number of repurchased shares, and determine the time and duration of repurchase, etc.; wherein, the repurchased Shares may be resold, used for equity incentive plans or cancelled for purposes permitted by laws, regulations and regulatory rules, and the specific disposal method shall be decided by the Board in accordance with the law;
 - (ii) Notify creditors and issue announcements in accordance with the requirements of the relevant laws, regulations, normative documents and the Articles of Association;
 - (iii) Open overseas share and capital accounts and carry out the related changes of foreign exchange registration procedures;
 - (iv) Carry out the relevant approval and filing procedures as required by regulatory authorities and the stock exchanges in the place where the shares of the Company are listed;

- (v) Carry out, execute and implement all such documents, do all such acts and things or take any steps as they consider desirable, necessary or expedient in connection with and to give effect to the repurchase of shares in accordance with the requirements of relevant laws and regulations and the listing rules of the stock exchanges in the place where the shares of the Company are listed;
 - (vi) Handle the cancellation of repurchased Shares, reduce registered capital, amend relevant provisions of the Articles of Association regarding total share capital and equity structure, and fulfill the relevant registration and filing procedures required by law in China and abroad;
 - (vii) Implement the procedure for holding repurchased Shares as treasury shares, including but not limited to establishing a separate account in the CCASS to hold such repurchased H Shares as treasury shares, and issuing clear written instructions to the H Share Registrar and relevant brokers to update the records to ensure that the repurchased H Shares held in the CCASS are clearly marked as treasury shares; and
 - (viii) Within the scope of the above authorization, the Board may sub-authorize the Chairman or the authorized personnel by the Chairman to sign and handle other documents and matters related to the repurchase of shares.
- (e) For the purpose of this resolution, the “**Relevant Period**” means the period from the passing of this resolution at the EGM of the Company, until whichever is the earlier of:
- (i) Upon conclusion of the 2026 annual general meeting of the Company; or
 - (ii) The time at which the authorization regarding the repurchase of H Shares is revoked or varied by a special resolution of the Shareholders at a general meeting of the Company.”
3. To consider and, if thought fit, pass with or without amendments, the following resolution regarding the proposed granting of general mandate to the Board to issue H Shares:

“**THAT:**

- (a) Subject to the conditions set forth in paragraph (b) and (c) below, the exercise by the Board during the Relevant Period (as defined below) of all the powers of the Company to separately or concurrently allot, issue and/or deal with additional H Shares (including but not limited to ordinary shares and convertible securities) and/or to sell or transfer treasury shares of the Company (if any), and make or grant offers, agreements, or options in relation to such Shares, based on the market condition and the needs of the Company;

- (b) The aggregate nominal value of additional H Shares to be conditionally or unconditionally issued or allotted by the Board (whether pursuant to the exercise of options or otherwise) shall not exceed 10% of the aggregate nominal value of the total issued Shares (including A Shares and H Shares but excluding any treasury shares) as of the date of approval of this resolution at the EGM;
- (c) The Board may only exercise the powers under the general mandate if it complies with the PRC Company Law, the PRC Securities Law, the Measures for the Administration of Registration of Securities Issuance by Listed Companies (《上市公司證券發行註冊管理辦法》), the Listing Rules, other applicable laws, regulations and/or requirements of all relevant government authorities, and the Articles of Association, and is subject to approval by competent authorities;
- (d) Subject to the abovementioned conditions, the Board is hereby authorized to:
 - i. Formulate and implement a detailed issuance plan, including but not limited to the class of the new Shares to be issued, pricing mechanism and/or issuance price (including price range), number of Shares to be issued, allottees and use of proceeds, time of issuance, period of issuance, specific subscription methods, the pre-emptive subscription ratio of existing Shareholders and other specific matters relating to the issuance;
 - ii. Engage intermediate agencies for share issuance related matters, approve and execute all acts, deeds, documents or other matters necessary, appropriate, desirable or associated with the share issuances, review and approve, amend in accordance with the requirements of regulatory authorities within or outside the PRC and sign on behalf of the Company, agreements related to Share issuance, including but not limited to placing and underwriting agreement and engagement agreements of intermediate agencies;
 - iii. Approve and execute, on behalf of the Company, statutory documents in relation to share issuance to be submitted to regulatory authorities, carry out relevant approval procedures as required by regulatory authorities and places where the Company is listed, and complete all necessary filings, registrations and records with the relevant governmental authorities of Hong Kong and/or any other regions and jurisdictions (if applicable);
 - iv. Amend or authorize another person (and his/her sub-authorizers) to amend the agreements and statutory documents referred to in paragraphs (ii) and (iii) above as required by regulatory authorities within or outside the PRC;

- v. Amend or authorize another person (and his/her sub-authorizers) to approve, execute, and make, or cause to execute and make, all documents, deeds, and matters relating to the allotment, issuance, and dealing of any new shares pursuant to the general mandate described above, to handle necessary formalities, and take other necessary actions; and
 - vi. Within the scope of the above authorization, the Board may also authorize the Chairman and his sub-authorizers to decide and handle other matters related to the issuance of additional H shares of the Company.
- (e) For the purpose of this resolution, “**Relevant Period**” refers to the period from the passing of this resolution as an ordinary resolution at the EGM until whichever is the earlier of:
- i. The conclusion of the 2026 annual general meeting of the Company;
 - ii. The revocation or variation of the authority under this resolution by passing of a resolution at a general meeting of the Company.

If, prior to the expiry of the Relevant Period, the Board and/or authorized persons have signed necessary documents, completed necessary procedures, or taken relevant actions regarding a specific share issuance, and such documents, procedures, or actions may need to be performed, carried out, or continue until the end of the aforementioned Relevant Period, then for the purpose of that specific issuance, the Relevant Period will be extended accordingly, and this mandate will be deemed to remain in effect until the final completion of the matter or the expiry of the relevant agreement or document. However, such extension will not apply to other new issuances under this mandate.”

4. To consider and approve the proposed application for comprehensive credit facilities and provision of guarantee for the Company and subsidiaries.

Details of the above resolutions proposed at the EGM are contained in the Circular, which is available on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.biocytogen.com.cn).

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
*Chairman of the Board, Chief Executive Officer and
Executive Director*

Hong Kong, June 4, 2026

Notes:

1. Unless the context otherwise stated, capitalized terms used in this notice shall have the meanings as those defined in the circular (the “**Circular**”) of the Company dated June 4, 2026.

Registered H Shareholders are requested to provide a valid email address of himself/herself/itself or his/her/its proxy (except for the appointment of the chairman of the EGM) for the proxy to receive the login access code to participate online in the eVoting Portal.

Registered H Shareholders will be able to attend the EGM, vote and submit questions online via the designated website (<https://evoting.vistra.com>) by using the username and password provided on the notification letter sent by the Company.

Non-registered holders whose H Shares are held in the CCASS through banks, brokers, custodians or HKSCC may also be able to attend the EGM, vote and submit questions online. In this regard, they should consult directly with their banks, brokers custodians, nominees or HKSCC Nominees Limited through which their shares are held (as the case may be) (collectively the “**Intermediary**”) and instruct the Intermediary to appoint them as proxy or corporate representative to attend and vote at the EGM electronically and in doing so, they will be asked to provide their email address, before the time limit required by the relevant Intermediary. Details regarding the eVoting Portal including the login details will be emailed to them by the Company’s H Share Registrar, Tricor Investor Services Limited.

2. The register of H Shareholders of the Company will be closed from Monday, June 22, 2026 to Thursday, June 25, 2026, both days inclusive, in order to determine the eligibility of the H Shareholders to attend and vote at the EGM to be held at 2:00 p.m. on Thursday, June 25, 2026. If H Shareholders wish to be eligible to attend and vote at the EGM, all transfer documents of H Shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company’s H share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration before 4:30 p.m. on Thursday, June 18, 2026. Shareholders whose names appear on the register of H Shareholders of the Company on Thursday, June 25, 2026 shall be entitled to attend and vote at the EGM.
3. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.
4. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his attorney duly authorised in writing. If the Shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.
5. In order to be valid, the form of proxy for H Shareholders, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company’s H share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, or via the designated website (<https://evoting.vistra.com>) by using the username and password provided on the notification letters sent by the Company as soon as possible and in any event no later 2:00 p.m. on Wednesday, June 24, 2026 (Hong Kong time) or no less than 24 hours before the time appointed for holding the above mentioned meeting or any adjournment thereof. Completion and return of a form of proxy will not preclude a H Shareholder from attending in person and voting at the EGM or any adjournment thereof, should they so wish.
6. All resolutions at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.
7. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this notice, the Board comprises Dr. Shen Yuelel as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.